Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 7Primary Myelofibrosis 6Solid Tumors 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Neoplasm Metastasis 3Lymphoma 3Small Cell Lung Carcinoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 2Leukemia 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Solid Tumor 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Cyclosporins 14Biopsy 14Alemtuzumab 14thymoglobulin 13venetoclax 11sargramostim 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Myeloproliferative Disorders × navitoclax × Clear all
NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡